Press Releases
Excerpt from the Press Release: WILMINGTON, Del., Dec. 30, 2024 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”), a clinical-stage biopharmaceutical company, today announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted…
Read More
Technology Discovers Antigen-Reactive T Cell Receptors with High Efficiency Excerpt from the Press Release: PHILADELPHIA, Jan. 3, 2025 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania developed a new screening technology, Aptamer-based T Lymphocyte Activity Screening and SEQuencing (ATLAS-seq), to better identify antigen-reactive T…
Read More
New model and vector could be instrumental in transforming the lives of XLSA patients and those with a broad spectrum of other diseases Excerpt from the Press Release: PHILADELPHIA, Jan. 2, 2025 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a first of its kind…
Read More
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination…
Read More
Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated…
Read More
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / Jaguar…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial…
Read More
Excerpt from the Press Release: PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer…
Read More
Studies will assess ST-067 in acute myeloid leukemia or myelodysplastic syndrome and in multiple myeloma Preclinical data to be presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition support the potential therapeutic use of ST-067 in hematologic cancers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.–(BUSINESS…
Read More
More than 20 presentations from top academic and pharma institutions worldwide will demonstrate how innovations like Mission Bio’s Tapestri Platform are driving breakthroughs in hematology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 5, 2024 – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the full list of…
Read More